focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Portfolio Update

7 Jun 2021 07:00

Portfolio Update

The Board notes that on 3 June 2021 Arecor Therapeutics plc ("Arecor"), one of Oxford Technology 3 VCT Plc’s (“OT3”) investee companies, floated on AIM raising £20m via a placing at 226p per Arecor share. The flotation was a success and the Arecor bid price at close had risen to 238p per Arecor share.

The most recently published unaudited net asset value (NAV) for OT3 at 30 November 2020 was 38.4p per share.

Compared to this last published OT3 NAV, the impact of the Arecor flotation in isolation is an increase in the OT3 NAV of £371k, or 5.5p per OT3 share.

Further detail – including an updated OT3 NAV as at 28 February 2021 and 31 May 2021 – will be available in the annual report which is expected to be released towards the end of this month. 

For further information contact:

Oxford Technology Management

Lucius Cary

01865 784466

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.